Literature DB >> 35703961

Prospective Implementation of Standardized Post-Hepatectomy Care Pathways to Reduce Opioid Prescription Volume after Inpatient Surgery.

Timothy P DiPeri1, Timothy E Newhook, Elsa M Arvide, Whitney L Dewhurst, Morgan L Bruno, Yun Shin Chun, Hop S Tran Cao, Jeffrey E Lee, Jean-Nicolas Vauthey, Ching-Wei D Tzeng.   

Abstract

BACKGROUND: Among the goals of prospectively implemented post-hepatectomy care pathways was a focus on patient-centric opioid reduction. We sought to evaluate the impact of pathway implementation on opioid volumes in the last 24-hour period and discharge prescriptions. STUDY
DESIGN: This is a retrospective cohort study comparing a prospective cohort ("POST," September 2019 through February 2020) treated after pathway implementation to a historical cohort of hepatectomy patients ("PRE," March 2016 through December 2017) before our 2018 departmental opioid reduction efforts. Opioid volumes in the last 24 hours and prescribed at discharge were converted to oral morphine equivalents (OME) and compared between cohorts.
RESULTS: There were 276 PRE and 100 POST patients. There was a similar proportion of major (PRE-34.1% vs POST-40%) and minimally invasive hepatectomies (PRE-19.9% vs POST-11%, p = 0.122). Implementation was associated with a shorter length of stay (median 5 d PRE vs 4 d POST, p < 0.001). Standardized opioid weaning was associated with a lower median last 24-hour OME (20 mg PRE vs 10 mg POST, p = 0.001). Using a standardized discharge calculation, median discharge OME were lower (200 mg PRE vs 50 mg POST, p < 0.001). More POST patients were discharged opioid-free (6.9% PRE vs 21% POST, p < 0.001).
CONCLUSIONS: Implementation of post-hepatectomy care pathways was associated with a 50% reduction in last 24-hour OME, which, combined with a standardized discharge calculation, was associated with an overall 75% reduction in discharge opioid volumes and tripled opioid-free discharges. These data suggest that no-cost, reproducible pathways can be considered in abdominal operations with similar incisions/length of stay to decrease variation in opioid dosing while prioritizing patient-centric opioid needs.
Copyright © 2022 by the American College of Surgeons. Published by Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35703961      PMCID: PMC9205619          DOI: 10.1097/XCS.0000000000000231

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.532


  26 in total

1.  Clinical Factors Associated With Practice Variation in Discharge Opioid Prescriptions After Pancreatectomy.

Authors:  Timothy E Newhook; Timothy J Vreeland; Whitney L Dewhurst; Xuemei Wang; Laura Prakash; Chun Feng; Morgan L Bruno; Michael P Kim; Thomas A Aloia; Jean-Nicolas Vauthey; Jeffrey E Lee; Matthew H G Katz; Ching-Wei D Tzeng
Journal:  Ann Surg       Date:  2020-07       Impact factor: 12.969

2.  Guidelines for Patient-CenteredOpioid Prescribing and Optimal FDA-Compliant Disposal of Excess Pills after Inpatient Operation: Prospective Clinical Trial.

Authors:  Eleah D Porter; Sarah Y Bessen; Ilda B Molloy; Julia L Kelly; Niveditta Ramkumar; Joseph D Phillips; Andrew P Loehrer; Matthew Z Wilson; Rian M Hasson; Srinivas J Ivatury; Jessica R Henkin; Richard J Barth
Journal:  J Am Coll Surg       Date:  2021-02-25       Impact factor: 6.113

3.  Educating surgical oncology providers on perioperative opioid use: A departmental survey 1 year after the intervention.

Authors:  Bradford J Kim; Heather A Lillemoe; Timothy E Newhook; Whitney L Dewhurst; Elsa M Arvide; Matthew H G Katz; Thomas A Aloia; Jean-Nicolas Vauthey; Jeffrey E Lee; Ching-Wei D Tzeng
Journal:  J Surg Oncol       Date:  2020-05-23       Impact factor: 3.454

4.  Wide Variation and Overprescription of Opioids After Elective Surgery.

Authors:  Cornelius A Thiels; Stephanie S Anderson; Daniel S Ubl; Kristine T Hanson; Whitney J Bergquist; Richard J Gray; Halena M Gazelka; Robert R Cima; Elizabeth B Habermann
Journal:  Ann Surg       Date:  2017-10       Impact factor: 12.969

5.  Performance of a modified three-level classification in stratifying open liver resection procedures in terms of complexity and postoperative morbidity.

Authors:  Y Kawaguchi; K Hasegawa; C-W D Tzeng; T Mizuno; J Arita; Y Sakamoto; Y S Chun; T A Aloia; N Kokudo; J-N Vauthey
Journal:  Br J Surg       Date:  2019-10-11       Impact factor: 6.939

6.  Risk-stratified clinical pathways decrease the duration of hospitalization and costs of perioperative care after pancreatectomy.

Authors:  Jason W Denbo; Morgan Bruno; Whitney Dewhurst; Michael P Kim; Ching-Wei Tzeng; Thomas A Aloia; Jose Soliz; Barbara Bryce Speer; Jeffrey E Lee; Matthew H G Katz
Journal:  Surgery       Date:  2018-05-25       Impact factor: 3.982

7.  Inpatient Opioid Use After Pancreatectomy: Opportunities for Reducing Initial Opioid Exposure in Cancer Surgery Patients.

Authors:  Timothy E Newhook; Whitney L Dewhurst; Timothy J Vreeland; Xuemei Wang; Jose Soliz; B Bryce Speer; Shannon Hancher-Hodges; Chun Feng; Morgan L Bruno; Michael P Kim; Thomas A Aloia; Jean-Nicolas Vauthey; Jeffrey E Lee; Matthew H G Katz; Ching-Wei D Tzeng
Journal:  Ann Surg Oncol       Date:  2019-06-26       Impact factor: 5.344

8.  Implementation of a Quality Improvement Initiative to Decrease Opioid Prescribing in General Surgery.

Authors:  Liese C C Pruitt; Douglas S Swords; Sathya Vijayakumar; Barbara Ostlund; Jeannette Prochazka; Nathan G Richards; Brian T Bucher; David E Skarda
Journal:  J Surg Res       Date:  2019-10-24       Impact factor: 2.192

9.  Patient-centered Opioid Prescribing: Breaking Away From One-Size-Fits-All Prescribing Guidelines.

Authors:  Josh Bleicher; Sean M Stokes; Benjamin S Brooke; Robert E Glasgow; Lyen C Huang
Journal:  J Surg Res       Date:  2021-03-18       Impact factor: 2.417

Review 10.  Prescription Opioid Analgesics Commonly Unused After Surgery: A Systematic Review.

Authors:  Mark C Bicket; Jane J Long; Peter J Pronovost; G Caleb Alexander; Christopher L Wu
Journal:  JAMA Surg       Date:  2017-11-01       Impact factor: 14.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.